Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units (TALViSoP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Number of patients in mobile palliative care units have pain of both nociceptive and neuropathic origin. In certain cases, procedures of locoregional analgesia can be helpful.
The Purpose of this study is to evaluate the impact of techniques of locoregional analgesia in a palliative population
| Condition | Intervention |
|---|---|
|
Pain |
Drug: opioids |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Supportive Care |
| Official Title: | Procedures of Locoregional Analgesia and Quality of Life in Palliative Care |
- Change in patients global quality of life [ Time Frame: 1 week after first injection ] [ Designated as safety issue: No ]To evaluate the change in patients global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL. Evaluations will take place before the procedure of locoregional analgesia and 1 week after.
- change in patient's global quality of life [ Time Frame: 2 days and 1 week after procedure ] [ Designated as safety issue: No ]
- evaluate the change in EORTC QLQ-C15 PAL score, assessed before the procedure of locoregional analgesia and 1 week after.
- evaluate the change in patient's global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL at 48 hours and 1 week post-procedure.
- evaluate pain at 48 hours post-procedure
- evaluate the change in doses of conventional treatments at 1 week
| Estimated Enrollment: | 38 |
| Study Start Date: | April 2010 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
Cancer pain is a serious problem in the palliative population. In particular, pain due to compression or invasion of nerve tissue by metastasis is frequent and often unresponsive to oral drug therapy and even to epidural administration of opioids. In such refractory pain in a palliative setting, one modality that could be helpful is the use of technics of locoregional analgesia. Currently, they are routinely used for the management of acute postoperative pain and become to be more widely used for cancer surgery. For example, intrapleural intercostal nerve blocks after major lung resection or preincisional paravertebral blocks after breast surgery have been shown to improve pain control. However, locoregional analgesia is only occasionally used in chronic cancer pain.
The procedures used are epidural analgesia, rachianesthesia, or continuous nerve blocks. L-bupivacaine will be used. The procedure will be performed only if the injection test is positive.
The patients will be evaluated before and after the procedure, the patient being his/her own control. Evaluations will take place immediately before the procedure, then at 48 hours, 1 week and 1 month after the procedure.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient ≥ 18 years-old, male or female, whatever his/her ethnic group
- Patient with untreatable cancer
- Patient hospitalized in a palliative care unit, with a life expectancy ≥ 1 week
- Pain unresponsive to conventional treatments
- Effectiveness of the injection test
- Signed informed consent
Exclusion Criteria:
- Patients > 18 years-old
- Patients with pain other than cancer pain
- Patient's refusal
- Coagulation disorders
- Local infection
- Known hypersensitivity to local analgesics
- Inefficacy of the injection test.
- Contraindication for analgesics
Contacts and Locations| Contact: Gerard TERRIER, MD | gerard.terrier@chu-limoges.fr |
| France | |
| Centre Hospitalier Universitaire - Hôpital Saint André | Recruiting |
| Bordeaux, France | |
| Contact: Benoît BURUCOA, MD 05 56 79 58 58 benoit.burucoa@chu-bordeaux.fr | |
| Principal Investigator: Benoît BURUCOA, MD | |
| Centre Hospitalier de Châteauroux | Not yet recruiting |
| Châteauroux, France | |
| Contact: Hervé MIGNOT, MD 02 54 08 00 72 eadsp36@wanadoo.fr | |
| Principal Investigator: Hervé MIGNOT, MD | |
| Centre Hospitalier de Guéret | Recruiting |
| Guéret, France | |
| Contact: Jean-Marc BOURDEREAU, MD 05 55 51 87 65 | |
| Principal Investigator: Jean-Marc BOURDEREAU, MD | |
| CHU Limoges | Recruiting |
| Liomges, France | |
| Contact: Gérard TERRIER, MD 05 55 05 66 13 gerard.terrier@chu-limoges.fr | |
| Principal Investigator: Gérard TERRIER, MD | |
| Sub-Investigator: Dominique GROUILLE, MD | |
| Centre Hospitalier Local | Recruiting |
| Saint Leonard de Noblat, France | |
| Contact: Jean Luc LASSALLE, MD 05 55 56 43 02 jl.lassalle@medsyn.fr | |
| Principal Investigator: Jean Luc LASSALLE, MD | |
| Centre Hospitalier de Tulle | Recruiting |
| Tulle, France | |
| Contact: Philippe MADDALENO, MD 05 55 29 80 74 soinspalliatifs@ch-tulle.fr | |
| Principal Investigator: Philippe MADDALENO, MD | |
| Study Chair: | Gérard TERRIER, MD | CHU Limoges |
More Information
No publications provided
| Responsible Party: | University Hospital, Limoges |
| ClinicalTrials.gov Identifier: | NCT01094912 History of Changes |
| Other Study ID Numbers: | I08014/TALViSoP |
| Study First Received: | March 26, 2010 |
| Last Updated: | February 27, 2013 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Limoges:
|
Cancer pain |
Additional relevant MeSH terms:
|
Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants |
ClinicalTrials.gov processed this record on May 19, 2013